« Silence Therapeutics’ stuttering effort to generate clinical data on SLN124 in myelodysplastic syndrome (MDS) has conked out. Facing recruitment challenges, the RNAi specialist has decided to stop enrollment in the MDS arm of an early-phase clinical trial to focus on thalassemia and polycythemia vera. »
In May 2021, Silence Therapeutics completed the GEMINI phase 1 study of SLN124 in healthy volunteers. Data from the study showed SLN124 was safe and effective in reducing plasma iron levels and had a long duration of action.
Critical Illness cover and Polycythemia Vera
